Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 10 versus DYANAVEL XR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 10 versus DYANAVEL XR 5.
DYANAVEL XR 10 vs DYANAVEL XR 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
None Documented
None Documented
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant